Development of a new topical system: Drug-in-cyclodextrin-in-deformable liposome

Gillet, Aline; Grammenos, Angeliki; Compère, Philippe; Évrard, Brigitte; Piel, Géraldine

doi:10.1016/j.ijpharm.2009.06.027

Cited by 77 publications

(32 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The suspension was kept overnight for complete hydration of the vesicles. Placebo formulations of the same composition without drug were also prepared (18)(19)(20)(21)(22)(23). The batch composition of the prepared vesicles for the prescreening study is shown in Table II.…”

Section: Formulation Of Transethosomes and Other Vesiclesmentioning

confidence: 99%

See 1 more Smart Citation

Systematic Development of Transethosomal Gel System of Piroxicam: Formulation Optimization, In Vitro Evaluation, and Ex Vivo Assessment

et al. 2016

View full text Add to dashboard Cite

Abstract. Piroxicam is used in the treatment of rheumatoid arthritis, osteoarthritis, and other inflammatory diseases. Upon oral administration, it is reported to cause ulcerative colitis, gastrointestinal irritation, edema and peptic ulcer. Hence, an alternative delivery system has been designed in the form of transethosome. The present study describes the preparation, optimization, characterization, and ex vivo study of piroxicam-loaded transethosomal gel using the central composite design. On the basis of the prescreening study, the concentration of lipids and ethanol was kept in the range of 2-4% w/v and 0-40% v/v, respectively. Formulation was optimized by measuring drug retention in the skin, drug permeation, entrapment efficiency, and vesicle size. Optimized formulation was incorporated in hydrogel and compared with other analogous vesicular (liposomes, ethosomes, and transfersomes) gels for the aforementioned responses. Among the various lipids used, soya phosphatidylcholine (SPL 70) and ethanol in various percentages were found to affect drug retention in the skin, drug permeation, vesicle size, and entrapment efficiency. The optimized batch of transethosome has shown 392.730 μg cm −2 drug retention in the skin, 44.312 μg cm −2 h −1 drug permeation, 68.434% entrapment efficiency, and 655.369 nm vesicle size, respectively. It was observed that the developed transethosomes were found superior in all the responses as compared to other vesicular formulations with improved stability and highest elasticity. Similar observations were noted with its gel formulation.

show abstract

Section: Formulation Of Transethosomes and Other Vesiclesmentioning

confidence: 99%

“…The skin was then washed with saline and kept in pH 7.4 phosphate buffer saline for further use (16,20,29).…”

Section: Ex Vivo Permeation Studymentioning

confidence: 99%

Systematic Development of Transethosomal Gel System of Piroxicam: Formulation Optimization, In Vitro Evaluation, and Ex Vivo Assessment

et al. 2016

View full text Add to dashboard Cite

show abstract

“…Size-exclusion separation [23] was applied to separate the free drug from the drug encapsulated in liposomes. Briefly, Sephadex G-50 was loaded into a 2.5 ml syringe and centrifuged at 2000 rpm for 3min to obtain a dehydrated column.…”

Section: Drug Encapsulation Efficiency (Ee)mentioning

confidence: 99%

The potential use of novel chitosan-coated deformable liposomes in an ocular drug delivery system

Chen

Pan

et al. 2016

Colloids and Surfaces B: Biointerfaces

View full text Add to dashboard Cite

“…Deformable liposomes made of soybean phosphatidylcholine or dimyristoylphosphatidylcholine and sodium deoxycholate as edge activator were compared to classical non-deformable liposomes. In comparison with non-deformable liposomes, these new vesicles showed improved encapsulation efficiency, good stability and higher in vitro diffusion percentages of encapsulated drug [63]. The release kinetics is directly correlated to the encapsulation efficiency, which is closely related to the betamethasone concentration in cyclodextrin complex solution [64].…”

Section: Liposomal Carriersmentioning

confidence: 93%

Innovative Formulations for the Controlled and Site-specific Delivery of Antiinflammatory Drugs

Serpe¹,

Canaparo²,

Foglietta³

et al. 2013

CPD

View full text Add to dashboard Cite

Pharmaceutical technology has introduced a promising pathway in the future of medicinein particular nanotechnological innovations have provided the opportunity to design and develop efficient drug delivery systems able to target and treat several diseases, including those mediated by inflammation. The engineering of drug delivery systems can be used to target tissues involved in the pathology under treatment, to avoid early drug biological environmental degradation and to modulate drug pharmacokinetics. Glucocorticoids and non-steroidal anti-inflammatory drugs are the most commonly prescribed drug categories worldwide for the treatment of disorders associated with inflammation.Although glucocorticoids can be highly effective in treating inflammation, their systemic application is limited due to the high incidence of serious adverse effects, mainly in long-term treatment. Non-steroidal anti-inflammatory drugs are a heterogeneous group of compounds and most of them have unfavorable pharmacokinetics and pharmacodynamics, leading to adverse effects, such as gastrointestinal disorders. Therefore, the need for drug delivery systems for long term administration of anti-inflammatory drugs witha well-controlled release profile is evident. The aim of this review is to assess innovative colloidal drugs carriers, in particular liposomes and nanoparticles, with special focus on site-specific delivery for particularly problematic tissues such as the gastrointestinal tract, joints and eyes.3

show abstract

Development of a new topical system: Drug-in-cyclodextrin-in-deformable liposome

Cited by 77 publications

References 19 publications

Systematic Development of Transethosomal Gel System of Piroxicam: Formulation Optimization, In Vitro Evaluation, and Ex Vivo Assessment

Systematic Development of Transethosomal Gel System of Piroxicam: Formulation Optimization, In Vitro Evaluation, and Ex Vivo Assessment

The potential use of novel chitosan-coated deformable liposomes in an ocular drug delivery system

Innovative Formulations for the Controlled and Site-specific Delivery of Antiinflammatory Drugs

Contact Info

Product

Resources

About